Cargando…
Evaluating the treatment of metastatic colorectal cancer with monoclonal antibodies
The ability to tailor biologic therapy based on the status of tumor biomarkers and monoclonal antibodies has become very important in the last years. The role of tumor biomarkers in treating colorectal cancer, specifically the K-RAS gene, was identified. K-RAS had a higher interest after Lievre and...
Autores principales: | Popa, C, Ionescu, S, Mihăilă, D, Gal, I, Potecă, T, Simion, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391878/ https://www.ncbi.nlm.nih.gov/pubmed/22802884 |
Ejemplares similares
-
Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010) -
Radiolabelled monoclonal antibodies in the treatment of metastatic cancer
por: Goldenberg, D.M.
Publicado: (2007) -
Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis
por: Rosa, Bruno, et al.
Publicado: (2015) -
Economic evaluation of monoclonal antibody in the management of colorectal cancer in Malaysia
por: Natrah, MS, et al.
Publicado: (2012) -
CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
por: Kang, Sora, et al.
Publicado: (2023)